流感最新消息N°552

GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS) RSV SARS-CoV-2 Influenza Co-circulation SUMMARY (Based on data reported to WHO for week 44, ending 02 November 2025) Globally, influenza and SARS-CoV-2 activity remained low in week 44. Influenza predominated all areas with positivity around 10% in the northernhemisphere temperate and subtropical areas, and over 10% in the tropical areas and southern hemisphere temperate and subtropical areas. [Figures 1a, 1b,1c and 1d] . qInfluenza Globally, influenza activity remained low, with influenza A viruses continuing to predominate. [Figure 2] In the northern hemisphere, influenza activity remained low in most countries. Influenza percent positivity was elevated in a few countries in CentralAmerica and the Caribbean, Northern Africa, Northern Europe, Southern and Eastern Asia, and was over 30% in Western, Eastern and Middle Africa,Western and South-East Asia. Small increases in activity were observed in countries in Central America and the Caribbean, Western and MiddleAfrica, Europe and Asia. [Figures 3 and 4] In the southern hemisphere, influenza activity remained low and stable in most countries with elevated positivity (>10%) in a single country inTemperate South America and two countries in Eastern Africa and percent positivity over 30% in a single country in South-East Asia. Small increasesin activity were observed in single countries in Temperate South America, Middle and Eastern Africa. [Figures 3 and 4] In the zones with elevated positivity, influenza A(H1N1)pdm09 predominated in Central America and the Caribbean, Northern and Middle Africawhereas influenza A(H3N2) was predominant in Temperate South America, Western Africa, Northern Europe, Western, Southern and South-East Asia.Influenza A(H1N1)pdm09 and influenza A(H3N2) were codominant in Eastern Africa. [Figures 5 and 6] qSARS-CoV-2Globally, SARS-CoV-2 positivity increased but remained at low levels, with some countries reporting elevated positivity (>10%) in Tropical and Temperate South America, South West and Eastern Europe, and Eastern Asia. Percent positivity was over 30% in one country in South West Europeand Western Asia. Increase in activity was reported in single countries in South-West Europe and Western Asia. [Figures 7 and 8] qRespiratory Syncytial Virus (RSV)RSV percent positivity remained elevated in Central America and the Caribbean with two countries reporting positivity over 30%, and single countries in Western and Eastern Africa and Eastern Asia. Compared to the previous reporting period, RSV positivity remained stable across most countries,with increases in activity in a few countries in Central America and the Caribbean and one country in South West Europe. [Figures 9 and 10] RSVand influenza activity were both elevated in one country Central America and the Caribbean and one country in Western Africa. Co-circulation of influenza and SARS-CoV-2 1a) Weekly numbers of influenza and SARS-CoV-2 virus specimens tested and percent positivity at the global level(last 12 months) 1c) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Tropical areas 1b) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Northern hemispheretemperate and subtropical areas 1d) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Southern hemispheretemperate and subtropical areas Influenza 2) Weekly numbers of influenza virus positive specimens by type and subtype and percent positivity at the globallevel (last 12 months) 4) Change in proportions of specimens that testedpositive for influenza (year-week:2025-44) 3) Proportions of specimens that tested positive forinfluenza (year-week:2025-44) 6) Weekly distribution of influenza virus types andsubtypes by geographic zone (last 12 months) 5) Proportions of influenza virus types and subtypes byinfluenza transmission zones (year-week:2025-44) SARS-CoV-2 7) Proportions of specimens that tested positive forSARS-CoV-2 (year-week:2025-44) 8) Change in proportions of specimens that testedpositive for SARS-CoV-2 (year-week:2025-44) Respiratory syncytial virus 9) Proportions of specimens that tested positive for RSV(year-week:2025-44) 10) Change in proportions of specimens that testedpositive for RSV (year-week:2025-44) Additional information Data and methods The data presented in this report originates from virologic surveillance conducted by countries, areas, and territories (CATs) andsubmitted to WHO FluNet through participation or collaboration with the Global Influenza Surveillance and Response System(GISRS). These CATs employ diverse methodologies to monitor respiratory virus activity, which may result in variations betweenthis report and other surveillance summaries published elsewhere. This report includes virologic data from bothsentinel surveillance and other systematically conducted surveillance. Dueto differe